Palbociclib · Regulatory label update

FDA supplemental approval: Ibrance (Efficacy)

U.S. Food and Drug Administration · June 24, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA issued a supplemental approval for palbociclib (Ibrance) on 24 June 2026 on the basis of efficacy, authorizing three tablet formulations (75 mg, 100 mg, 125 mg). This record is a regulatory action only and does not disclose the clinical trial results, endpoints, or comparative data that supported the decision.

What was studied

Regulatory label update.

Key findings

Supplemental approval granted for palbociclib (Ibrance) on efficacy grounds, 24 June 2026 Approved formulations: 75 mg, 100 mg, and 125 mg oral tablets Sponsor: Pfizer; NDA 212436

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This record confirms regulatory authorization but does not provide the clinical evidence, efficacy endpoints, or comparative benefit data needed to assess impact on clinical practice. Clinicians should refer to the full product label and supporting clinical dossier for safety and efficacy information.

Plain-language summary

FDA supplemental approval for palbociclib (Ibrance) indicates a regulatory action granting efficacy-based authorization, but the record does not contain clinical trial data, endpoints, or comparative outcomes.

Reported figures

Quoted from the source exactly as published.

Approval status date2026-06-24

Submission classEfficacy

Clinical bottom line

Caveats

Record does not contain clinical trial results, efficacy endpoints, hazard ratios, or absolute benefit measures.
No population, sample size, comparator, or study design disclosed.
Regulatory action status does not imply practice-changing evidence; supporting trials and outcomes must be reviewed separately.
Record does not describe the indication(s) or prior approval history for palbociclib.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no study design reported.

Directness

insufficient

Record does not describe the clinical evidence underlying approval.

Consistency

insufficient

No comparative or replicate data provided in this record.

Risk of bias

insufficient

Regulatory record does not assess bias in underlying trials.

Sample adequacy

insufficient

No sample size or population data reported in this record.

Source abstract

Drugs@FDA record for application NDA212436. This is a regulatory action record, not a clinical study. Brand name: IBRANCE. Active ingredient: PALBOCICLIB. Sponsor: PFIZER. Submission type: SUPPL (supplement). Submission class: Efficacy. Approval status date: 2026-06-24. Products: IBRANCE, TABLET, ORAL, PALBOCICLIB 125MG; IBRANCE, TABLET, ORAL, PALBOCICLIB 75MG; IBRANCE, TABLET, ORAL, PALBOCICLIB 100MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

PalbociclibPfizer